title: In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability.
abstract: BACKGROUND
  Various pancreatic enzyme preparations are used for the treatment of pancreatic insufficiency but their bioequivalence is often unknown.
  
  
  OBJECTIVE
  To determine in vitro the pH-dependent release and acid resistance of enzymes from three commercially available pancreatin capsules, two containing enteric-coated (Creon 25000; Eurobiol 25000) and one uncoated (Eurobiol 12500) microspheres.
  
  
  METHODS
  Dissolution experiments were performed at pH values ranging from 4.0 to 5.8. Lipase, chymotrypsin and amylase activities were measured in the solution as a function of time.
  
  
  RESULTS
  Eurobiol 25000 started to release its enzymes significantly at pH 5.0 (t(1/2) = 71 min), whereas the enzymes from Creon 25000 were only released at higher pH value (5.4; t(1/2) = 49.2 min). Unlike chymotrypsin, lipase and amylase were highly sensitive to acidic conditions at the lowest pH values tested. Both enzymes were also found to be sensitive to proteolytic inactivation at the highest pH values tested. Overall, Eurobiol 25000 released higher amounts of active amylase and lipase than Creon 25000 at the pH values usually found in duodenal contents. The uncoated Eurobiol 12500 preparation was, however, the only one that could immediately release rather high levels of active chymotrypsin and lipase at low pH (4.5).
  
  
  CONCLUSIONS
  These findings suggest that pH-sensitive enteric-coated pancreatin products containing similar amounts of enzymes might not be bioequivalent depending on the pH of duodenal contents.
authors.affiliation: Laboratory of Enzymology at Interfaces and Physiology of Lipolysis, CNRS-UPR 9025-IBSM, Marseille, France.
authors.forename: A
authors.initials: A
authors.lastname: Aloulou
authors.forename: D
authors.initials: D
authors.lastname: Puccinelli
authors.forename: J
authors.initials: J
authors.lastname: Sarles
authors.forename: R
authors.initials: R
authors.lastname: Laugier
authors.forename: Y
authors.initials: Y
authors.lastname: Leblond
authors.forename: F
authors.initials: F
authors.lastname: Carrière
mesh_terms: D000681:Amylases / Q000032:analysis; D000818:Animals; D001682:Biological Availability; D002918:Chymotrypsin / Q000032:analysis; D004386:Duodenum / Q000378:metabolism; D010188:Exocrine Pancreatic Insufficiency / Q000188:drug therapy / Q000378:metabolism; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008049:Lipase / Q000032:analysis; D008863:Microspheres; D010184:Pancreatic Extracts / Q000493:pharmacokinetics*; D020799:Pancrelipase / Q000493:pharmacokinetics*; D012995:Solubility; D013608:Tablets, Enteric-Coated
chemical_list: C056841:Eurobiol; D005765:Gastrointestinal Agents; D010184:Pancreatic Extracts; D013608:Tablets, Enteric-Coated; D020799:Pancrelipase; D008049:Lipase; D000681:Amylases; D002918:Chymotrypsin